Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.

被引：0
|
作者：
Nastoupil, Loretta J.
Kamdar, Manali K.
Chavez, Julio C.
Ghesquieres, Herve
Ghosh, Monalisa
Holmes, Houston
Guillermo, Armando Lopez
Martinez-Lopez, Joaquin
Novak, Urban
Ribrag, Vincent
Roddie, Claire
机构：
[1] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA
[2] Univ Colorado, Canc Ctr, Aurora, CO USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Hop Lyon Sud, Lyon, France
[5] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[6] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] Hosp 12 Octubre, Madrid, Spain
[9] Univ Hosp Bern, Med Oncol, Inselspital, Bern, Switzerland
[10] Gustave Roussy Canc Ctr DITEP, Villejuif, France
[11] UCL, London, England
[12] Emory Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA USA
[13] Hackensack Univ, Hackensack Meridian Hlth Sch Med, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[14] Mayo Clin, Phoenix, AZ USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Univ klinikum Carl Gustav Carus Dresden, Dresden, Germany
[17] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[18] Bristol Myers Squibb Co, Celgene, Boudry, Switzerland
[19] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7526
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Improved quality of life (QOL) with lisocabtagene maraleucel (liso- cel), a CD19-directed chimeric antigen receptor T cell therapy, compared with standard of care (SOC) using salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the phase 3 TRANSFORM study
    Glass, Bertram
    Abramson, Jeremy
    Johnston, Patrick B.
    Kamdar, Manali
    Ibrahimi, Sami
    Izutsu, Koji
    Arnason, Jon
    Mutsaers, Pim
    Lunning, Matthew
    Braverman, Julia
    Liu, Fei Fei
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Guo, Shien
    Shi, Ling
    Solomon, Scott
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 220 - 220
  • [32] Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
    Palomba, M. Lia
    Jun, Monika P.
    Garcia, Jacob
    Lymp, James
    McGarvey, November
    Gitlin, Matthew
    Pelletier, Corey
    Nguyen, Andy
    BLOOD, 2020, 136
  • [33] Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/HealthRelated Quality of Life from the Outreach Study
    Linhares, Yuliya
    Liu, Fei Fei
    Freytes, Cesar
    Cherry, Mohamad
    Shi, Ling
    Liao, Weiqin
    Braverman, Julia
    Espinola, Ricardo
    Vedal, Min
    Mattar, Bassam
    BLOOD, 2022, 140 : 10930 - 10931
  • [34] Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study
    Stepan, Lara
    Ansari, Sahar
    Okal, Abood
    Dell'Aringa, Justine
    Thompson, Ethan
    Crotta, Alessandro
    Chow, Victor A.
    Abramson, Jeremy S.
    Kamdar, Manali
    Chabon, Jacob J.
    Hogan, Gregory
    Kurtz, David M.
    Alizadeh, Ash A.
    Peiser, Leanne
    BLOOD, 2023, 142
  • [35] Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
    Dahiya, Saurabh
    Hirayama, Alexandre V.
    Schuster, Stephen J.
    Reguera Ortega, Juan Luis
    Morschhauser, Franck
    Garcia-Sancho, Alejandro Martin
    Kuruvilla, John
    Izutsu, Koji
    Maria Barbui, Anna
    Borchmann, Peter
    Mielke, Stephan
    Cartron, Guillaume
    Ghesquieres, Herve
    Goto, Hideki
    Varadarajan, Indumathy
    Kamdar, Manali
    Isufi, Iris
    Farazi, Thalia
    Kao, Grace Shih Hui
    Vedal, Min
    Bhatnagar, Rashmi
    Nishii, Rina
    Papuga, Jessica
    Lia Palomba, M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S462 - S463
  • [36] Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
    Locke, Frederick L.
    Chou, Justin
    Vardhanabhuti, Saran
    Perbost, Regis
    Dreger, Peter
    Hill, Brian T.
    Lee, Catherine
    Zinzani, Pier Luigi
    Kroeger, Nicolaus
    Lopez-Guillermo, Armando
    Greinix, Hildegard
    Zhang, Wangshu
    Tiwari, Gayatri
    To, Christina Ann
    Cheng, Paul C.
    Bot, Adrian
    Shen, Rhine
    Filosto, Simone
    Galon, Jerome
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)
    Godwin, John E.
    Mattar, Bassam
    Maris, Michael
    Bachier, Carlos
    Stevens, Don
    Hoda, Daanish
    Varela, Juan C.
    Cherry, Mohamad
    Fanning, Suzanne
    Essell, James
    Yimer, Habte
    Courtright, Jay
    Sharman, Jeff P.
    Espinola, Ricardo
    Mailley, Connor
    Avilion, Ariel
    Ogasawara, Ken
    Ou, San-San
    Shaughnessy, Paul
    BLOOD, 2021, 138
  • [38] Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
    Dahiya, Saurabh
    Spiegel, Jay Y.
    Lee, Dasom
    Mohammed, Turab
    Lutfi, Forat
    Goyal, Anmol
    Hana, Caroline
    Chavez, Julio C.
    Ionescu, Filip
    Frank, Matthew J.
    Bharadwaj, Sushma
    Sandoval-Sus, Jose
    Beitinjaneh, Amer M.
    Lekakis, Lazaros J.
    McGuirk, Joseph P.
    Locke, Frederick L.
    Miklos, David B.
    Jain, Michael D.
    BLOOD, 2023, 142
  • [39] Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7
    Locke, Frederick L.
    Oluwole, Olalekan O.
    Kuruvilla, John
    Thieblemont, Catherine
    Morschhauser, Franck
    Salles, Gilles
    Rowe, Steven P.
    Vardhanabhuti, Saran
    Filosto, Simone
    To, Christina
    Cheng, Paul
    Schupp, Marco
    Korn, Ronald
    Kersten, Marie Jose
    BLOOD, 2022, 140
  • [40] Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
    Ghobadi, Armin
    Munoz, Javier
    Westin, Jason
    Locke, Frederick L.
    Miklos, David B.
    Rapoport, Aaron P.
    Perales, Miguel-Angel
    Reagan, Patrick M.
    McGuirk, Joseph P.
    Jacobson, Caron A.
    Kersten, Marie Jose
    Avivi, Irit
    Peng, Andrew
    Schupp, Marco
    To, Christina
    Oluwole, Olalekan O.
    BLOOD, 2022, 140 : 1595 - 1597
12345